119,35 €
0,34 % gestern
L&S, 30. Oktober, 22:52 Uhr
ISIN
US64125C1099
Symbol
NBIX
Berichte

Neurocrine Biosciences, Inc. Aktie News

Neutral
Seeking Alpha
2 Tage alt
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Todd Tushla Kyle Gano - CEO & Director Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Sanjay Keswani - Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Paul Matteis - Stifel, Nicolaus & Company, In...
Positiv
24/7 Wall Street
2 Tage alt
Neurocrine Biosciences posts standout Q3 beat as INGREZZA and CRENESSITY drive 28% product sales growth.
Neutral
PRNewsWire
2 Tage alt
Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Growth CRENESSITY® (crinecerfont) Third-Quarter 2025 Net Product Sales of $98 Million with 540 Total New Patient Enrollment Start Forms SAN DIEGO , Oct. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences...
Positiv
Seeking Alpha
13 Tage alt
Neurocrine Biosciences is rated BUY, driven by strong INGREZZA sales, Prenepsi growth, and a promising late-stage neuropsychiatry pipeline. NBIX's Q2 2025 revenue reached $682 million, with INGREZZA contributing 91% and Prenepsi expanding its rare-disease market presence. Robust cash reserves of $1.8 billion and disciplined expense management position NBIX to self-fund pipeline innovation and f...
Neutral
PRNewsWire
14 Tage alt
Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous treatment with INGREZZA 40 mg achieved a ≥50% improvement in the Abnormal Involuntary Movement Scale Total Score INGREZZA is the only vesicular monoamine transporter 2 (VMAT2) inhibitor that allows...
Neutral
PRNewsWire
23 Tage alt
Conference Call and Webcast Scheduled for Tuesday, October 28 SAN DIEGO , Oct. 7, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.
Neutral
PRNewsWire
24 Tage alt
SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial experience in the biopharmaceutical industry, will be responsible for developing and executing the sales and marke...
Neutral
PRNewsWire
25 Tage alt
Once-daily INGREZZA treatment was generally well tolerated and showed early and sustained improvements in chorea severity Findings presented at 2025 MDS International Congress of Parkinson's Disease and Movement Disorders®  SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an establis...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen